SI
The startup develops biopharmaceuticals that target synaptic proteins to reverse synapse loss associated with brain injuries and neurodegenerative diseases. By restoring brain connections, the company enables patients to regenerate synapses, improving cognitive function and quality of life.
Updated 3 months ago
Funding
$13.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops biopharmaceuticals that target synaptic proteins to reverse synapse loss associated with brain injuries and neurodegenerative diseases. By restoring brain connections, the company enables patients to regenerate synapses, improving cognitive function and quality of life.